REPL
NASDAQ · Biotechnology
Replimune Group Inc
$6.98
+0.09 (+1.31%)
Open$6.82
Previous Close$6.89
Day High$7.18
Day Low$6.82
52W High$14.80
52W Low$2.68
Volume—
Avg Volume1.38M
Market Cap706.00M
P/E Ratio—
EPS$-3.44
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+409.3% upside
Current
$6.98
$6.98
Target
$35.55
$35.55
$27.68
$35.55 avg
$47.36
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |
| Rev Growth | -3.7% | +3.8% | +9.6% |
| Debt/Equity | 1.03 | 0.84 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |